Squarepoint Ops LLC Akero Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $1.19 Million - $2.09 Million	-67,152 Reduced 89.36%	7,997 $202,000
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $855,195 - $3.78 Million	75,149 New	75,149 $1.75 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $258,840 - $348,916	-6,945 Reduced 25.69%	20,091 $768,000
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $904,083 - $1.48 Million	27,036 New	27,036 $1.48 Million
Q1 2021 May 17, 2021	SELL	$24.04 - $34.19 $957,152 - $1.36 Million	-39,815 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $749,329 - $891,618	29,830 Added 298.75%	39,815 $1.03 Million
Q3 2020 Nov 16, 2020	SELL	$30.79 - $39.92 $157,121 - $203,711	-5,103 Reduced 33.82%	9,985 $307,000
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $82,967 - $115,335	-4,310 Reduced 22.22%	15,088 $376,000
Q1 2020 May 15, 2020	SELL	$12.8 - $27.05 $500,608 - $1.06 Million	-39,110 Reduced 66.85%	19,398 $411,000
Q4 2019 Feb 14, 2020	BUY	$17.37 - $27.27 $688,442 - $1.08 Million	39,634 Added 209.99%	58,508 $1.3 Million
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $318,781 - $563,955	18,874 New	18,874 $429,000

168

72.7M

178K

164K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.33B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.